FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Mammen Mathai 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/3/2022 

 3. Issuer Name and Ticker or Trading Symbol JOHNSON & JOHNSON [JNJ]
(Last)       (First)       (Middle)
ONE JOHNSON & JOHNSON PLAZA		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Pharm, R&D /
(Street)
NEW BRUNSWICK, NJ 08933      
(City)             (State)             (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  32477.0000  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Options (Right to Buy) (1) 2/12/2021  2/11/2028  Common Stock  28927.0000  $129.5100  D   
Employee Stock Options (Right to Buy) (1) 2/11/2022  2/11/2029  Common Stock  36098.0000  $131.9400  D   
Employee Stock Options (Right to Buy) (1) 2/10/2023  2/10/2030  Common Stock  58130.0000  $151.4100  D   
Employee Stock Options (Right to Buy) (1) 2/28/2024  2/28/2031  Common Stock  43149.0000  $164.6200  D   
Restricted Share Units (2) 2/3/2023   (2) Common Stock  35951.0000   (2) D   
Restricted Share Units (2) 2/8/2024   (2) Common Stock  3929.0000   (2) D   
Restricted Share Units (2) 2/10/2023   (2) Common Stock  4545.0000   (2) D   
Restricted Share Units (2) 2/11/2022   (2) Common Stock  7418.0000   (2) D   

Explanation of Responses:
(1)  Vested and exercisable on the third anniversary of the date of the grant.
(2)  Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.

Remarks:
mammenpoa1.txt

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mammen Mathai
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933

EVP, Pharm, R&D

Signatures
Raavi Deol, as attorney-in-fact for Mathai Mammen 1/13/2022
**Signature of Reporting Person Date
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Johnson and Johnson Charts.